Milestone in kidney health: Discovery of Ginsenoside M1 In the Treatment of Lupus Nephritis Awarded a US Patent

TAIPEI, Taiwan, /PRNewswire/ -- Wellhead Biological Technology Corp. (WBTC) has made a milestone discovery in the treatment of kidney disease with its development of small molecule medicine using ginsenosides.

After 20 years of research and development, our discovery of M1 ginsenoside extracted from ginseng as an effective treatment of patients with lupus nephritis was awarded a patent by the United States Patent Office (Patent No.: US 9,844,560B2, USE OF GINSENOSIDE M1 FOR TREATING LUPUS NEPHRITIS). This exciting discovery will complement current treatments of lupus nephritis which are limited to relieving symptoms, which may turn a new page in the treatment of kidney patients worldwide.

Ginseng is regarded as the king herb or adaptogen in traditional Chinese or native Indian medicine. The adaptogen effect could be attributed to the diversity of ginseng saponins, ie, ginsenosides, the main medicinal ingredients in ginseng, as each subclass of ginsenoside may function differently. Through its extensive expertise in ginsenoside fermentation and extraction, WBTC have tested various ginsenoside as effective agents in improving renal function. We discovered that ginsenoside M1 has the highest effectiveness in improving renal function in patients. In our study of nephritis, we found that ginsenoside M1 molecule could repair glomerular function and even reverse the decline of glomerular filtration rate (GFR).

There are currently about 700 million chronic patients with kidney diseases in the world. The rate of dialysis in Taiwan has been the highest in the world for many years. At present, the current medication for treating kidney diseases are limited to reducing the symptoms but does not have the capability to heal the underlying causes.

WBTC plans to apply for clinical trials in the near future. We believe our discovery will bring good news to renal patients worldwide.

For further information, please contact Dr. James Lee at tel +866-3-4990100 or via email at jameslee@wellhead-bms.com.

About Wellhead Biological Technology Corp.
WBTC is located in Taoyuan, Taiwan, is a world leader in ginseng research, with a US subsidiary in Weston, WI. It has a high-quality R&D team that specializes in ginsenoside production, and holds US and Taiwan patents on “functional group fungal bioconversion method,” for producing ginsenosides Rh2, Rg3, and other rare saponins. For more information on the WBTC, visit us online at http://en.wellhead-bms.com or call +886-3-4990100.

Contact:
Dr. James Lee
Wellhead Biological Technology Corp.
+886-3-4990100 | jameslee@wellhead-bms.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/milestone-in-kidney-health-discovery-of-ginsenoside-m1-in-the-treatment-of-lupus-nephritis-awarded-a-us-patent-300769115.html

SOURCE Wellhead Biological Technology Corp.